Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-metabolizing enzyme that is widely distributed in normal or malignant tissues and contributes to immunologic tolerance and immune escape. However, in hepatocellular carcinoma (HCC), the characteristics and mechanism of IDO1 expression have not been well defined. In this study, IDO1 expression in tumor cells (T-IDO1) was frequently detected (109/112) by immunohistochemistry in formalin-fixed paraffin-embedded specimens from HCC patients, and the expression patterns were mostly focal (102/109). Expression of T-IDO1 was significantly associated with the infiltration of CD8+ T cells (P = .043), as well as younger age (<50 years old, P = .02). It was also found that IDO1 had diffuse expression in inflammatory cells in all specimens, which were defined as antigenpresenting cells. Significant correlations among IDO1, IFNG, and CD8A transcriptional levels were observed in freshly resected HCC specimens; moreover, no constitutive IDO1 expression was detected in HCC cell lines until stimulated by interferon-γ through the JAK2-STAT1 signaling pathway, but not type I interferon. Survival analyses showed that increased T-IDO1 and CD8+ T cell infiltration were significantly associated with superior overall survival (OS) (T-IDO1, P = .003; CD8+ T cells, P = .004), and T-IDO1 expression is an independent prognosis factor in both OS and diseasefree survival (OS, P = .007; disease-free survival, P = .044). These findings indicated that T-IDO1 expression in HCC is common and is dominantly driven by the host antitumor immune response, which is a favorable prognostic factor in HCC.
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| INTRODUC TI ON
Hepatocellular carcinoma is a typical malignancy that slowly unfolds on a background of chronic inflammation mainly triggered by exposure to infectious agents (hepatotropic viruses) or toxic compounds (ethanol). 1 In the tumorigenic process, the accumulation of genomic alterations creates various neoantigens that can elicit host antitumor immune responses. 2 Indeed, intense lymphocytic infiltration within the tumor, especially CD8+ T cells, as a favorable predictor in HCC, is a major effector against HCC. 3, 4 Unexpectedly, tumors appear to establish an immunosuppressive microenvironment to brake host immune killing. Recently, immune checkpoint inhibitors blocking cytotoxic T-lymphocyte-associated antigen-4 and programmed cell death-1/programmed cell deathligand 1 have been widely applied in HCC practice, but they have been less effective than anticipated, suggesting that additional immunosuppressive fences might need to be overcome to maximize therapeutic efficacy in HCC. 5, 6 A recent study showed that IDO1 plays a key role in adaptive resistance to immune checkpoint inhibitors in HCC. 7 Indoleamine 2,3-dioxygenase 1 is a rate-limiting enzyme in the catabolism of the essential amino acid tryptophan along the kynurenine pathway, and it is widely distributed in various types of tumors. 8, 9 Broad evidence has indicated that local tryptophan deprivation and the accumulation of kynurenines produced by IDO1 elevation crucially facilitate the escape of malignant tumors from host immune killing with multiple effects, including the suppression of T and NK cells, the generation and activation of regulatory T cells and myeloid-derived suppressor cells, and the promotion of tumor angiogenesis. [10] [11] [12] [13] [14] [15] As an immune escape mechanism, high constitutive IDO1 expression, driven by intrinsic cellular changes such as gene mutations associated with carcinogenesis, represents an adverse prognostic factor in colorectal cancer, endometrial cancer, ovarian carcinoma, and a number of other cancers. [16] [17] [18] [19] [20] In contrast, in breast carcinoma, early stage cervical cancer, and melanoma, IDO1 expression is accompany the host antitumor immune response, and it tends to positively correlate with survival. [21] [22] [23] [24] However, in another study, the high inductive IDO1 expression in primary melanoma negatively affected progression-free survival. 25 Under the heterogeneity of tumor gene mutations and the tumor microenvironment, both constitutive and inducible IDO1 expression can co-exist regulated by tumor intrinsic and extrinsic mechanisms, reflecting either the absence or presence of antitumor immunity in specific tumor microenvironments. Thus, higher IDO1 expression could correlate with either worse or improved prognosis in different tumors. 26 Based on previous studies, the features and mechanisms of IDO1 expression in HCC tumor cells remain controversial, and its prognostic value must also be clarified. [27] [28] [29] In this study, we characterize IDO1 expression in both tumor cells (T-IDO1) and inflammatory cells (I-IDO1) in a series of 112 surgically resected HCCs. In vitro and ex vivo experiments were carried out to explore the mechanism controlling T-IDO1 expression, and survival analyses were undertaken to explore the significance of T-IDO1 and I-IDO1 expression in prognosis.
| MATERIAL AND ME THODS

| Cell lines and culture
Two cell lines derived from human HCC (Hep3B and Huh7; ATCC, Manassas, VA, USA) were authenticated by short tandem repeat profiling-based PCR and were analyzed to determine IDO1 protein expression. All cells were cultured at 37°C, 5% CO 2 in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin. These cell lines have been tested for mycoplasma contamination by PCR. 
| Patients and samples
| Western blot analysis
| Reverse transcription-PCR
Tumor samples were immediately snap-frozen in liquid nitrogen after harvesting. Total RNA was extracted using TRIzol reagent (#T9424, 
| Immunohistochemistry
After deparaffinization, rehydration, and washing of the 5-μm sections, endogenous peroxidase was blocked (3% H 2 O 2 for 10 minutes), and microwave antigen retrieval was undertaken in Tris-EDTA (pH 9.0).
The sections were first incubated with blocking serum at room tem- Group) at 4°C overnight. The second incubation was carried out using a goat anti-mouse/rabbit Ab and visualized with DAB, following counterstaining with hematoxylin after serial rinsing. The observation and images acquisition of these sections were carried out by advanced research microscope (Nikon Eclipse 80i; Nikon, Tokyo, Japan).
| Evaluation of immunostaining parameters
To evaluate IDO1 expression in tumor and inflammatory cells separately, each IHC section was examined by two independent pathologists in the five most representative areas, and the average count was calculated. To reduce the influence of subjective factors, ImageJ computer software (National Institutes of Health, Bethesda, MD, USA) was used to aid in analyzing the images, and the tumor cells and nontumor cells were separated according to morphology. Expression of IDO1 was evaluated quantitatively on the basis of the percentage of positive areas. According to the results of the receiver operating characteristic curve curves, high T-IDO1 and I-IDO1 expression were defined as ≥5.80% and ≥6.00%, respectively ( Figure S1 ). CD8+ T lymphocytes were counted in a microscopic field at 400×, the median number (10 counts/high-power field) of CD8 infiltrations in the cohort as a cut-off value. Additionally, CD4+
T lymphocytes and NK cells were also counted in another 20 specimens at 400× to evaluate the association between them and IDO1.
| Method using ImageJ
Images were opened at high magnification in ImageJ software, and the open image type was set to RGB color. The option "Color Threshold" was turned on, and "Hue," "Saturation," and "Brightness" were adjusted so that threshold color completely covered the ROI. Then the number of pixels in the ROI was analyzed, and the proportion of the ROI area to total area was calculated (the total number of pixels/high magnification image was 2560 × 1920).
| Immunofluorescence
After deparaffinization, rehydration and washing of the sections, microwave antigen retrieval was carried out in Tris-EDTA (pH 9.0).
Sections were first incubated with blocking serum at room tempera- AffiniPure goat anti-rabbit IgG (1:100; E032420, EarthOx). Following counterstaining with DAPI after serially rinsing with 1× PBST, images were acquired in a microscopic field at 600×. The observation and images acquisition of these sections were carried out using a confocal laser scanning microscope (Olympus Fluoview FV1000;
Olympus, Tokyo, Japan).
| Statistical analyses
All statistical analyses were performed using SPSS statistical soft- Overall survival was defined as the length of time from the surgery date to death or until the last follow-up (censored). Disease-free survival was defined as the length of time from the surgery date to recurrence, death, or until the last follow-up (censored).
The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit public platform (www.researchdata.org.cn), with the approval RDD number as RDDB2018000434.
| RE SULTS
| Clinical profiles of patients
The demographic and clinical characteristics of the patients and tumors are presented in 
| Expression pattern of IDO1 in HCC tissue samples
Indoleamine 2,3-dioxygenase 1 expression was present in 97.3%
(109/112) of cases within the tumor compartment and showed a predominantly cytoplasmic staining pattern. As shown in Figure 1 , three major expression patterns of T-IDO1 were observed by IHC: focal expression in 91% (102/112) of cases ( Figure 1A,B) ; discrete expression in 6.3% (7/112) of cases ( Figure 1C,D) ; and absence in 2.7% (3/112) of cases ( Figure 1E ). According to the cut-off value, T-IDO1 expression was low for 54 patients (48.2%) and high for 58 patients (51.8%).
Placenta was used as a positive control for IDO1 expression ( Figure 1F ).
| Correlation between IDO1 and clinicopathological features
CD8+ T cell infiltration ( Figure S2 ) and clinicopathological features were submitted to correlation analysis with T-IDO1 expression. The T-IDO1-positive area was larger in samples with abundant CD8+ T cell infiltration than in those with infrequent CD8+ T cell infiltration (P = .043, Figure 2A ). In the clinicopathological features, only age was a significant factor affecting T-IDO1 expression (P = .02; Figure 2B -D and Table S1 ).
Hepatitis B was the main cause of HCC in our cohort, the T-IDO1-positive area showed no significant difference between the HBV (+) and HBV (−) groups ( Figure 2E ). There was no association between T-IDO1 and I-IDO1 ( Figure 2F ).
| Expression of IDO1 reflects antitumor immunity in HCC
To elucidate the mechanism underlying the association between were also identified ( Figure S3 ; n = 371). 31 In vitro experiments 
| Associations of IDO1 expression and CD8+ tumor-infiltrating lymphocytes with HCC patient prognosis
Given that CD8+ T cell infiltration positively correlated with prognosis and T-IDO1 expression in our study, we next examined whether tumor invasion might be partially restrained in high IDO1 expression HCC. Favorable OS and DFS intervals were highlighted by KaplanMeier curves (P = .003 and P = .045, respectively; Figure 5A ,B) for patients with a high T-IDO1 expression compared with those with low expression. HCC patients with high I-IDO1 expression also have superior OS and DFS outcomes (P < .001 and P = .002, respectively; Figure 5C ,D). In keeping with the previous findings, patients with high levels of CD8+ T cell infiltration had significantly prolonged OS and DFS (P = .004 and P = .027, respectively; Figure 5E ,F), confirming the role of the cytotoxic T cell in the eradication of HCC. 3 Multivariate analyses showed that T-IDO1 expression was an independent predictor of OS and DFS (P = .007 and P = .044, respectively; Tables S2, S3 ).
| D ISCUSS I ON
In HCC, previous research has described the prognostic significance of T-IDO1 expression. Unfortunately, the conclusions are contradictory, and little is known regarding the prognostic value of I-IDO1 slowed. [40] [41] [42] Consistent with previous studies, local tryptophan deprivation produced by abundant IDO1 could also disturb tumor growth. 27, 43 We did not explore the potential mechanism because its inducible expression by APCs has been intensively studied, and it appears that no tumor specificity exists regarding I-IDO1 expression. 40, 44 Expression of I-IDO1 tends to be higher in HBV+ HCCs than in HBV− HCCs; however, in our study, there was no significant difference between the groups, which might be due to the small number of HBV− HCC patients included in our study. Yoshio and colleagues discovered that IDO1 was mainly induced by IFN-γ in patients with hepatitis B. 45 It was safely deduced that inflammatory cells could be stimulated with cytokines induced by HBV-infected hepatocytes and then by unregulated IDO1 expression. Hence, I-IDO1 expression comprehensively reflects the host immune response to the tumor and HBV, supporting that antiviral therapy could improve HCC patient prognosis. 46 There were some limitations in this study. A major limitation was its retrospective nature, which incurred the inevitable selection bias. To distinguish tumor and stroma, we did not analyze the entire section but included 5 high-power fields in a representative region, which might also have contributed to selection bias due to tumor heterogeneity. Because of poor uniformity of the IDO1 IHC Abs and evaluation methods, there is no widely accepted cut-off value for IDO1 expression in HCC; therefore, we defined one according to the present cohort, which could have led to the discrepancy between our results and other studies. The overwhelming majority cohort in our research is HBV-associated HCC, which is due to the high incidence of HCC associated with endemic HBV infection in China. 47 Our study revealed that IDO1 expression, which is common in HCC, is a positive survival predictor, and its expression is a counter-regulatory action to suppress the antitumor immune response. Thus, combined inhibition of IDO1 and immune checkpoints to boost host antitumor immune response could be a promising strategy in HCC treatment, and understanding of the mechanism of IDO1 expression would help us explore better combined strategies. 7, 23, 48 
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